I 
117TH CONGRESS 
2D SESSION 
H. R. 6710 
To direct the Secretary of Health and Human Services, acting through 
the Commissioner of Food and Drugs, to submit to Congress a report 
on barriers, including regulatory inefficiencies, to domestic manufacturing 
of active pharmaceutical ingredients, finished drug products, and devices, 
and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 11, 2022 
Ms. HERRELL (for herself, Mr. BANKS, Mr. MCKINLEY, Mr. HERN, Mrs. MIL-
LER of Illinois, Mr. HIGGINS of Louisiana, Mrs. MILLER-MEEKS, Mr. 
AUSTIN SCOTT of Georgia, Mr. DONALDS, Mr. CAWTHORN, Mr. NORMAN, 
Mr. LATURNER, Mr. KELLER, Mr. HUDSON, Mrs. CAMMACK, and Mr. 
GOHMERT) introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce 
A BILL 
To direct the Secretary of Health and Human Services, 
acting through the Commissioner of Food and Drugs, 
to submit to Congress a report on barriers, including 
regulatory inefficiencies, to domestic manufacturing of 
active pharmaceutical ingredients, finished drug prod-
ucts, and devices, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
VerDate Sep 11 2014 
20:29 Feb 24, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6710.IH
H6710
pamtmann on DSKBC07HB2PROD with BILLS
2 
•HR 6710 IH
SECTION 1. REPORT AND RECOMMENDATION ON BAR-
1
RIERS TO DOMESTIC MANUFACTURING OF 
2
MEDICAL PRODUCTS. 
3
(a) REPORT TO CONGRESS.—Not later than 180 days 
4
after the date of the enactment of this Act, the Secretary 
5
of Health and Human Services (in this section referred 
6
to as the ‘‘Secretary’’), acting through the Commissioner 
7
of Food and Drugs, shall submit to Congress a report on 
8
barriers, including regulatory inefficiencies, to domestic 
9
manufacturing of active pharmaceutical ingredients, fin-
10
ished drug products, and devices that are— 
11
(1) imported from outside of the United States; 
12
and 
13
(2) critical to the public health during a public 
14
health emergency declared by the Secretary under 
15
section 319 of the Public Health Service Act (42 
16
U.S.C. 247d). 
17
(b) CONTENT.—Such report shall— 
18
(1) identify factors that limit the manufac-
19
turing of active pharmaceutical ingredients, finished 
20
drug products, and devices described in subsection 
21
(a); and 
22
(2) recommend specific strategies to overcome 
23
the challenges identified under paragraph (1). 
24
VerDate Sep 11 2014 
20:29 Feb 24, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6710.IH
H6710
pamtmann on DSKBC07HB2PROD with BILLS
3 
•HR 6710 IH
(c) IMPLEMENTATION.—The Secretary may, to the 
1
extent appropriate, implement the strategies recommended 
2
under subsection (b)(2). 
3
(d) DEFINITION.—In this section, the term ‘‘active 
4
pharmaceutical ingredient’’ has the meaning given to such 
5
term in section 744A of the Federal Food, Drug, and Cos-
6
metic Act (21 U.S.C. 379j–41). 
7
Æ 
VerDate Sep 11 2014 
20:29 Feb 24, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H6710.IH
H6710
pamtmann on DSKBC07HB2PROD with BILLS
